Background: Infection with high-risk human papillomavirus (HR-HPV) may be higher in perinatally human immunodeficiency virus (HIV)-infected (PHIV) than HIV-uninfected (HU) adolescents because of long-standing immune deficiency. Methods: PHIV and HU females aged 12-24 years in Thailand and Vietnam were matched by age group and lifetime sexual partners. At enrollment, blood, cervical, vaginal, anal, and oral samples were obtained for HPV-related testing. The Wilcoxon and Fisher exact tests were used for univariate and logistic regression for multivariate analyses. Results: Ninety-three PHIV and 99 HU adolescents (median age 19 [18-20] years) were enrolled (June 2013-July 2015). Among PHIV, 94% were currently receiving antiretroviral therapy, median CD4 count was 593 (392-808) cells/mm3, and 62% had a viral load <40 copies/mL. Across anogenital compartments, PHIV had higher rates of any HPV detected (80% vs 60%; P = .003) and any HR-HPV (60% vs 43%, P = .02). Higher proportions of PHIV had abnormal Pap smears (eg, atypical squamous cells of unknown significance [ASC-US], 12% vs 14%; low-grade squamous intraepithelial neoplastic lesions, 19% vs 1%). After adjusting for ever being pregnant and asymptomatic sexually transmitted infections (STI) at enrollment, PHIV were more likely to have HR-HPV than HU (odds ratio, 2.02; 95% confidence interval, 1.09-3.77; P = .03). Conclusions: Perinatal HIV infection was associated with a higher risk of HR-HPV and abnormal cervical cytology. Our results underscore the need for HPV vaccination for PHIV adolescents and for prevention and screening programs for HPV and other STIs.
Background: Infection with high-risk human papillomavirus (HR-HPV) may be higher in perinatally human immunodeficiency virus (HIV)-infected (PHIV) than HIV-uninfected (HU) adolescents because of long-standing immune deficiency. Methods: PHIV and HU females aged 12-24 years in Thailand and Vietnam were matched by age group and lifetime sexual partners. At enrollment, blood, cervical, vaginal, anal, and oral samples were obtained for HPV-related testing. The Wilcoxon and Fisher exact tests were used for univariate and logistic regression for multivariate analyses. Results: Ninety-three PHIV and 99 HU adolescents (median age 19 [18-20] years) were enrolled (June 2013-July 2015). Among PHIV, 94% were currently receiving antiretroviral therapy, median CD4 count was 593 (392-808) cells/mm3, and 62% had a viral load <40 copies/mL. Across anogenital compartments, PHIV had higher rates of any HPV detected (80% vs 60%; P = .003) and any HR-HPV (60% vs 43%, P = .02). Higher proportions of PHIV had abnormal Pap smears (eg, atypical squamous cells of unknown significance [ASC-US], 12% vs 14%; low-grade squamous intraepithelial neoplastic lesions, 19% vs 1%). After adjusting for ever being pregnant and asymptomatic sexually transmitted infections (STI) at enrollment, PHIV were more likely to have HR-HPV than HU (odds ratio, 2.02; 95% confidence interval, 1.09-3.77; P = .03). Conclusions: Perinatal HIV infection was associated with a higher risk of HR-HPV and abnormal cervical cytology. Our results underscore the need for HPV vaccination for PHIV adolescents and for prevention and screening programs for HPV and other STIs.
Authors: Myron J Levin; Anna-Barbara Moscicki; Lin-Ye Song; Terrence Fenton; William A Meyer; Jennifer S Read; Edward L Handelsman; Barbara Nowak; Carlos A Sattler; Alfred Saah; David R Radley; Mark T Esser; Adriana Weinberg Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: Christina Carlander; Philippe Wagner; Veronica Svedhem; Kristina Elfgren; Katarina Westling; Anders Sönnerborg; Pär Sparén Journal: Int J Cancer Date: 2016-06-02 Impact factor: 7.396
Authors: A B Moscicki; J H Ellenberg; S H Vermund; C A Holland; T Darragh; P A Crowley-Nowick; L Levin; C M Wilson Journal: Arch Pediatr Adolesc Med Date: 2000-02
Authors: Zizipho Z A Mbulawa; Cari van Schalkwyk; Nai-Chung Hu; Tracy L Meiring; Shaun Barnabas; Smritee Dabee; Heather Jaspan; Jean-Mari Kriek; Shameem Z Jaumdally; Etienne Muller; Linda-Gail Bekker; David A Lewis; Janan Dietrich; Glenda Gray; Jo-Ann S Passmore; Anna-Lise Williamson Journal: PLoS One Date: 2018-01-02 Impact factor: 3.240
Authors: Chunqing Lin; Jiri Slama; Paula Gonzalez; Marc T Goodman; Ningshao Xia; Aimée R Kreimer; Ting Wu; Nancy A Hessol; Yurii Shvetsov; Ana P Ortiz; Beatriz Grinsztejn; Anna-Barbara Moscicki; Isabelle Heard; María Del Refugio González Losa; Erna M Kojic; Maarten F Schim van der Loeff; Feixue Wei; Adhemar Longatto-Filho; Zizipho A Mbulawa; Joel M Palefsky; Annette H Sohn; Brenda Y Hernandez; Katina Robison; Steve Simpson; Lois J Conley; Alexandra de Pokomandy; Marianne A B van der Sande; Racheal S Dube Mandishora; Lays P B Volpini; Alessandra Pierangeli; Byron Romero; Timothy Wilkin; Silvia Franceschi; Carmen Hidalgo-Tenorio; Reshmie A Ramautarsing; Ina U Park; Fernanda K Tso; Sheela Godbole; Kathleen W M D'Hauwers; Borek Sehnal; Lynette J Menezes; Sandra A Heráclio; Gary M Clifford Journal: Lancet Infect Dis Date: 2019-06-13 Impact factor: 25.071
Authors: Elisabeth McClymont; Arianne Y Albert; Christine Wang; Scott J Dos Santos; François Coutlée; Marette Lee; Sharon Walmsley; Nancy Lipsky; Mona Loutfy; Sylvie Trottier; Fiona Smaill; Marina B Klein; Mark H Yudin; Marianne Harris; Wendy Wobeser; Janet E Hill; Deborah M Money Journal: Int J STD AIDS Date: 2022-07-01 Impact factor: 1.456